Avaleht › Eesnäärmevähk › Oklahoma
Eesnäärmevähk kliinilised uuringud osariigis Oklahoma
24 uuringut haiguse Eesnäärmevähk jaoks otsivad osalejaid osariigis Oklahoma.
Linnad osariigis Oklahoma
Ametlik uuringutekst (inglise keeles)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
VärbamineFaas 1/2
Vanused 12 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT04585750Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 2. okt 2026 · NCT06931340Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
Vanused 40–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT06632977Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. sept 2026 · NCT03866382Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- Oklahoma Proton Center, Oklahoma City
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 29. sept 2026 · NCT01492972Protoacoustic Imaging For 3D Mapping
- OU Health Stephenson Cancer Center, Oklahoma City
VärbamineVaatlusuuring
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07832617A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Hightower Clinical, Oklahoma City
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 22. sept 2026 · NCT07213674Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Utica Park Urology, Tulsa
Värbamine
Vanused 18 ja vanemad · Mehed · Uuendatud 14. sept 2026 · NCT06511141Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Urologic Specialists, Tulsa
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 11. sept 2026 · NCT06056830Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 10. sept 2026 · NCT05946213The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineTerved vabatahtlikud oodatud
Vanused 45–75 · Kõik sood · Uuendatud 2. sept 2026 · NCT06995898Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
- OU Health Stephenson Cancer Center, Oklahoma City
VärbamineVaatlusuuring
Vanused 18–100 · Mehed · Uuendatud 26. aug 2026 · NCT06960798Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 19. aug 2026 · NCT04423211A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 7. aug 2026 · NCT06751329Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 14. juuli 2026 · NCT06592924Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
- University of Oklahoma HSC, Oklahoma City
Värbamine
Vanused 18 ja vanemad · Mehed · Uuendatud 1. apr 2026 · NCT06651359Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineFaas 2
Vanused 18 ja vanemad · Mehed · Uuendatud 29. jaan 2026 · NCT05806515Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 22. jaan 2026 · NCT06470243Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
VärbamineVaatlusuuring
Vanused 18 ja vanemad · Kõik sood · Uuendatud 17. dets 2025 · NCT07014618SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
VärbamineVaatlusuuring
Kõik vanused · Kõik sood · Uuendatud 28. okt 2025 · NCT03452774Connect2Care: Prostate Cancer Education and Screenings for African American Men
- TSET Health Promotion Research Center, Oklahoma City
Värbamine
Vanused 45–69 · Mehed · Uuendatud 25. sept 2025 · NCT07055165Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 11. sept 2025 · NCT03678025A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #13, Oklahoma City
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 5. sept 2025 · NCT05932862Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.